Workflow
舞茸
icon
Search documents
华绿生物:公司会通过不定期网络直播等方式进行产品推广
Zheng Quan Ri Bao· 2025-09-25 14:07
Group 1 - The company, Hualv Biotechnology, announced on September 25 that it will promote its products through periodic online live broadcasts [2] - The company's mushroom products are available for sale online through platforms such as Dingdong and Meituan, as well as in major wholesale markets nationwide [2] - The company encourages consumers to purchase its products [2]
华绿生物:目前同行业上市公司中仅公司工厂化生产舞茸产品
Zheng Quan Ri Bao Wang· 2025-09-25 13:44
证券日报网讯华绿生物(300970)9月25日在互动平台回答投资者提问时表示,根据公开披露的信息, 目前同行业上市公司中仅公司工厂化生产舞茸产品,除此之外公司暂未获知其他工厂化生产舞茸产品的 公司。 ...
华绿生物:目前同行业上市公司中仅本公司工厂化生产舞茸产品
Mei Ri Jing Ji Xin Wen· 2025-09-25 08:37
Group 1 - The core viewpoint is that Hualu Bio has achieved a breakthrough in the industrialized cultivation technology of Grifola frondosa (Maitake mushroom), positioning itself as a leader in the industry [2] - According to Hualu Bio, it is currently the only listed company in the industry that has implemented industrialized production of Maitake products, with no other companies known to have achieved this [2]
华绿生物(300970.SZ):公司舞茸产品暂未布局药物产业
Ge Long Hui· 2025-09-25 08:23
Core Viewpoint - The company Hualu Bio (300970.SZ) has stated that its maitake mushroom products are not currently positioned in the pharmaceutical industry [1] Company Summary - Hualu Bio has clarified its current strategic focus, indicating that it has not yet ventured into the pharmaceutical sector with its maitake mushroom products [1]
华绿生物股价跌5.01%,中信保诚基金旗下1只基金重仓,持有202.13万股浮亏损失157.66万元
Xin Lang Cai Jing· 2025-08-27 07:05
Group 1 - Core viewpoint: Hualu Bio experienced a 5.01% decline on August 27, with a stock price of 14.80 yuan per share and a total market capitalization of 1.779 billion yuan [1] - Company overview: Jiangsu Hualu Bio-Tech Group Co., Ltd. was established on June 8, 2010, and listed on April 12, 2021. The company specializes in the research, industrial cultivation, and sales of edible mushrooms [1] - Revenue composition: The main business revenue is derived from enoki mushrooms (69.15%), king oyster mushrooms (25.44%), maitake mushrooms (2.65%), other products (1.50%), and cordyceps flowers (1.26%) [1] Group 2 - Major shareholder: CITIC Prudential Fund's multi-strategy mixed fund (LOF) A (165531) increased its holdings by 1.2423 million shares in the second quarter, holding a total of 2.0213 million shares, which represents 2.18% of the circulating shares [2] - Fund performance: The fund has achieved a return of 41.61% year-to-date, ranking 893 out of 8194 in its category, and an annual return of 80.96%, ranking 656 out of 7963 [2] - Fund manager details: The fund manager Jiang Feng has a tenure of 5 years and 137 days, with a total asset scale of 5.782 billion yuan, while Wang Ying has a tenure of 8 years and 195 days, managing 3.835 billion yuan [3]
华绿生物8月26日获融资买入704.63万元,融资余额4817.30万元
Xin Lang Cai Jing· 2025-08-27 01:54
Company Overview - Jiangsu Hualv Biotechnology Group Co., Ltd. is located at 88 Lvdou Avenue, Siyang County, Jiangsu Province, established on June 8, 2010, and listed on April 12, 2021. The company's main business involves the research, industrial cultivation, and sales of edible mushrooms [1]. Financial Performance - For the first half of 2025, Hualv Biotechnology achieved operating revenue of CNY 499 million, representing a year-on-year growth of 7.78%. However, the net profit attributable to the parent company was a loss of CNY 53.69 million, a decrease of 19.79% compared to the previous period [2]. - Cumulatively, since its A-share listing, Hualv Biotechnology has distributed a total of CNY 76.79 million in dividends, with CNY 46.45 million distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders of Hualv Biotechnology reached 11,400, an increase of 11.49% from the previous period. The average number of circulating shares per person decreased by 10.31% to 8,162 shares [2]. - Among the top ten circulating shareholders, CITIC Prudential Multi-Strategy Mixed Fund (LOF) A ranked as the third-largest shareholder, holding 2.0213 million shares, an increase of 1.2423 million shares from the previous period [3]. Financing and Trading Activity - On August 26, Hualv Biotechnology's stock price increased by 0.78%, with a trading volume of CNY 50.68 million. The financing buy-in amount for the day was CNY 7.0463 million, while the financing repayment was CNY 5.4802 million, resulting in a net financing buy-in of CNY 1.5662 million. The total financing and securities lending balance reached CNY 48.173 million, accounting for 2.57% of the circulating market value, which is above the 70th percentile level over the past year [1]. - In terms of securities lending, there were no shares sold or repaid on August 26, with the securities lending balance also at zero, indicating a high level of inactivity in this area, exceeding the 90th percentile level over the past year [1].
华绿生物上半年营收4.99亿元同比增7.78%,归母净利润-5369.47万元同比降19.79%,毛利率下降3.75个百分点
Xin Lang Cai Jing· 2025-08-26 11:28
Core Viewpoint - Huagu Green Bio reported a revenue of 499 million yuan for the first half of 2025, reflecting a year-on-year growth of 7.78%, but the net profit attributable to shareholders was -53.69 million yuan, a decline of 19.79% compared to the previous year [1] Financial Performance - The basic earnings per share for the reporting period was -0.45 yuan, with a weighted average return on equity of -3.66% [2] - The company's gross margin for the first half of 2025 was -3.38%, down 3.75 percentage points year-on-year, while the net margin was -11.43%, a decrease of 1.63 percentage points from the same period last year [2] - In Q2 2025, the gross margin further declined to -16.18%, a year-on-year drop of 6.89 percentage points and a quarter-on-quarter drop of 23.58 percentage points; the net margin was -25.86%, down 2.64 percentage points year-on-year and down 26.58 percentage points quarter-on-quarter [2] Cost Structure - Total operating expenses for the first half of 2025 were 44.34 million yuan, a decrease of 3.13 million yuan compared to the previous year, with an expense ratio of 8.89%, down 1.37 percentage points year-on-year [2] - Sales expenses decreased by 15.35%, management expenses decreased by 13.61%, and R&D expenses decreased by 8.38%, while financial expenses increased significantly by 637.41% [2] Shareholder Information - As of the end of the first half of 2025, the total number of shareholders was 11,400, an increase of 1,171 households or 11.49% from the end of the previous quarter; the average market value held per household rose from 137,300 yuan to 153,400 yuan, an increase of 11.73% [3] Company Overview - Jiangsu Huagu Green Bio Technology Group Co., Ltd. was established on June 8, 2010, and listed on April 12, 2021; its main business involves the R&D, industrial cultivation, and sales of edible mushrooms [3] - The revenue composition of the main business includes enoki mushrooms (69.15%), king oyster mushrooms (25.44%), maitake mushrooms (2.65%), and others [3] - The company belongs to the agricultural, forestry, animal husbandry, and fishery industry, specifically in the planting sector focused on edible mushrooms [3]